Published in

Taylor and Francis Group, Free Radical Research, sup1(47), p. 3-27, 2013

DOI: 10.3109/10715762.2013.815348

Links

Tools

Export citation

Search in Google Scholar

Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation

Journal article published in 2013 by G. Vistoli ORCID, D. De Maddis, A. Cipak, N. Zarkovic, M. Carini, G. Aldini ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Abstract Advanced lipoxidation end-products (ALEs) and advanced glycoxidation end-products (AGEs) have a pathogenetic role in the development and progression of different oxidative based diseases including, diabetes, atherosclerosis and neurological disorders. AGEs and ALEs represent a quite complex class of compounds that are formed by different mechanisms, by heterogeneous precursors and that can be formed either exogenously or endogenously. There is a wide interest in AGEs and ALEs involving different aspects of research, among them: 1) set-up and application of analytical strategies to identify, characterize and quantify AGEs and ALEs in different pathophysiological conditions; 2) to elucidate the molecular basis of their biological effects; 3) to discover compounds able to inhibit AGEs/ALEs damaging effects not only as biological tools aimed at validating AGEs/ALEs as drug target, but also as promising drugs. All the above-mentioned research stages require a clear picture of the chemical formation of AGEs/ALEs but this is not simple, due to the complex and heterogeneous pathways, involving different precursors and mechanisms. In view of this intricate scenario, the aim of the present review is to group the main AGEs and ALEs and to describe, for each of them, the precursors and mechanisms of formation.